Our Why

“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological diseases.”

Søren Tulstrup, President and CEO

 

Latest news

Stockholm -1.60 HNSA   257.60 SEK
 
22Oct

Interim report for Jan - Sep 2020

29Oct

Hansa Biopharma Capital Markets Day

17Nov

Bryan Garnier European Healthcare Conference

Paris
18Nov

Jefferies Healthcare Conference

London
25Nov

Ökonomisk Ugebrev Life Science Conference

Copenhagen
02Feb

Interim report Jan-Dec 2020

08Apr

Annual Report 2020

22Apr

Interim report for Jan-Mar 2021

15Jul

Interim report for Jan-Jun 2021

21Oct

Interim report for Jan-Sep 2021

23Sep

ABG Small & Mid Cap Seminar

Copenhagen
16Sep

BofAML Global Healthcare Conference

London
15Sep

H.C. Wainwrigth conference

14Sep

Morgan Stanley Global Healthcare Conference

NYC (virtual)
09Sep

Citi’s Annual BioPharma Virtual Conference

Boston (virtual)
03Sep

Pareto Healthcare Conference

Stockholm
01Sep

Road Show Kempen (Virtual)

Benelux, Paris & Tel Aviv
14Aug

Nordea Small & Mid Cap Seminar

Stockholm (virtual)
16Jul

Interim report for Jan - Jun. 2020

Webcast
23Jun

Annual General Meeting

Click here to join the webinar at 15:00 hrs CET
16Jun

Citi's European Healthcare Conference

London (virtual)
27May

Redeye Orphan Drug Seminar

Stockholm (virtual)
26May

ABG Life Science Summit

Stockholm
19May

RBC Global Healthcare Conference (to be held virtually)

NYC
18May

UBS Global Healthcare Conference (to be held virtually)

New York City
28Apr

Interim Report Jan-Mar 2020

Webcast
21Apr

Kempen Lifescience Conference (Cancelled)

Amsterdam
02Apr

Annual Report 2019

26Mar

Kempen Expert call

04Mar

Carnegie Nordic Healthcare Seminar

Stockholm, Sweden
04Mar

Road Show

New York City
02Mar

Cowen Annual Health Care Conference

Boston
28Feb

Road Show Cowen

Dallas
27Feb

Road Show Cowen

Chicago
19Feb

Road Show Kempen

Tel Aviv
18Feb

Road Show Kempen

Paris
06Feb

Interim Report Oct-Dec 2019

23Jan

Road Show RBC

London
22Jan

SEB Annual Pharma & Biotech Seminar

Stockholm
16Jan

JP Morgan Global Healthcare conference

San Francisco
15Jan

JP Morgan Global Healthcare conference

San Francisco
14Jan

JP Morgan Global Healthcare conference

San Francisco
13Jan

JP Morgan Global Healthcare conference

San Francisco
08Jan

SEB Nordic Seminar

Copenhagen
05Dec

DNB Nordic-American Life Science Conference

NYC, USA
04Dec

Evercore Annual HealthCONx Conference

Boston, USA
20Nov

Jefferies Global Healthcare Conference

London, England
19Nov

Redeye Life Science Day

Stockholm
15Nov

NDRS Carnegie

Stockholm
14Nov

NDRS Kempen

Amsterdam & Zurich
12Nov

Bryan Garnier Healthcare Conference

Paris, France
04Nov

NDRS Morgan Stanley

US
01Nov

Interim Report 9 months 2019

Webcast
31Oct

Interim Report 9 months 2019

Webcast
20Sep

BofAML Global Healthcare Conference

London, England
15Sep

ESOT

Copenhagen, Denmark
12Sep

KoL Event

San Francisco, USA
10Sep

Morgan Stanley Global Healthcare Conference

New York, USA
06Sep

Goldman Sachs Biotech

London, England

Introduction to Hansa

Søren Tulstrup, President & CEO

left-photo-mask

Join Hansa

From our headquarters in Lund, Sweden, we reach around the world. Our dedicated team includes experienced and courageous specialists driven by our purpose to develop lifesaving and life altering therapies for patients living with rare immunological diseases.

Since our founding in 2007, we have worked in cross functional and agile teams. We are gender-balanced, representing a vast number of nationalities and see diversity as an enabler for reaching our corporate objectives. The recruitment of highly motivated, experienced and talented team players supports our development towards a fully integrated global biopharmaceutical company.

During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud.

Careers